IPI3/NIVO1

Phase 3Small molecule

VVastra Gotaland Region

IPI3/NIVO1 is one of 51 small molecule programs targeting Uveal Melanoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uveal MelanomaActive, not recruiting

Uveal MelanomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

90 competitors in Uveal Melanoma

#DrugCompanyPhaseTrials

DTIC-Dome

Bayer

Phase 3

5 2

Koselugo

AstraZeneca

Phase 3

2 3

Yervoy

Bristol-Myers Squibb

Phase 2

12 4

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

1 5

Opdivo

Bristol-Myers Squibb

Phase 2

9 6

KIMMTRAK

IImmunocore Ltd

Phase 3

5 7

Keytruda

Merck & Co.

Phase 2

6 8

Sutent

Pfizer

Phase 2

2 9

Nexavar

Bayer

Phase 2

2 10

Mekinist

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Recruiting

Uveal Melanoma

NCT06519266

Clinical

Trials by Indication[1]

Uveal Melanoma1 trial

PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases

Recruiting·VVastra Gotaland Region·Phase 3·NCT06519266·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IPI3/NIVO1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IPI3/NIVO1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IPI3/NIVO1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vastra Gotaland Region company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVastra Gotaland Region

IPI3/NIVO1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Uveal Melanoma1 trial

References

Drug Info

Quick Facts

Related News